Celera Researchers Investigating Genetic Risk Signature to Predict Atrial Fibrillation | GenomeWeb

Originally published April 15.

Researchers from Celera, working with a Swedish team from the Malmö Diet and Cancer study, have shown that a multi-gene signature could help doctors identify individuals at higher risk of developing atrial fibrillation (AF) in order to better guide treatment and other preventive interventions.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.